Schweiger Dermatology Group, Hackensack, New Jersey, USA.
Icahn School of Medicine at Mt. Sinai, New York, New York, USA.
J Cosmet Dermatol. 2024 Apr;23(4):1122-1130. doi: 10.1111/jocd.16018. Epub 2024 Feb 13.
The demand for nonsurgical facial rejuvenation options is growing, yet the periorbital region remains an area of relative unmet need. This review explores nonsurgical options for facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating age-related blepharoptosis as part of periorbital rejuvenation.
Advisors experienced in facial rejuvenation met to discuss existing literature on the upper face and periorbital rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating facial aging.
An array of nonsurgical options exist to address the signs of aging, including minimally invasive treatments, such as botulinum toxin injections and dermal fillers, and noninvasive therapy, such as lasers, chemical peels, and microdermabrasion. However, treating age-related ptosis in periorbital rejuvenation is mainly addressed surgically. The newly approved α-adrenergic receptor agonist oxymetazoline hydrochloride ophthalmic solution, 0.1%, provides a novel non-interventional approach to blepharoptosis.
Facial rejuvenation is highly sought-after in this post-pandemic era. Each nonsurgical treatment option has its advantages and drawbacks. A patient-centered approach is necessary to select the appropriate procedure considering the patient's concerns and aesthetic sensibilities. The eyes are an area of primary concern for patients, yet surgery is the gold standard for treating ptosis. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, is a safe and effective nonsurgical treatment for blepharoptosis.
对面部非手术年轻化选择的需求不断增长，但眶周区域仍然存在相对未满足的需求。本综述探讨了面部年轻化的非手术选择以及 0.1%羟甲唑啉盐酸滴眼剂在治疗与年龄相关的眼睑下垂作为眶周年轻化的一部分中的作用。
具有面部年轻化经验的顾问开会讨论了有关上面部和眶周年轻化以及 0.1%羟甲唑啉盐酸滴眼剂在治疗面部衰老中的作用的现有文献。
存在多种非手术选择来解决衰老迹象，包括微创治疗，如肉毒杆菌毒素注射和真皮填充剂，以及非侵入性治疗，如激光、化学换肤和微晶磨皮。然而，在眶周年轻化中治疗与年龄相关的下垂主要通过手术解决。新批准的 α-肾上腺素能受体激动剂 0.1%羟甲唑啉盐酸滴眼剂为眼睑下垂提供了一种新颖的非介入治疗方法。
在后疫情时代，对面部年轻化的需求很高。每种非手术治疗选择都有其优点和缺点。考虑到患者的关注和审美感受，需要采用以患者为中心的方法来选择合适的程序。眼睛是患者关注的主要区域，但手术是治疗下垂的金标准。0.1%羟甲唑啉盐酸滴眼剂是治疗眼睑下垂的一种安全有效的非手术治疗方法。
